X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with FDC LTD. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs FDC LTD. - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA FDC LTD. CIPLA/
FDC LTD.
 
P/E (TTM) x 43.5 17.3 251.6% View Chart
P/BV x 3.6 3.6 99.5% View Chart
Dividend Yield % 0.4 1.3 27.3%  

Financials

 CIPLA   FDC LTD.
EQUITY SHARE DATA
    CIPLA
Mar-17
FDC LTD.
Mar-14
CIPLA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs622144 433.4%   
Low Rs45879 580.1%   
Sales per share (Unadj.) Rs181.947.6 382.3%  
Earnings per share (Unadj.) Rs12.97.6 169.1%  
Cash flow per share (Unadj.) Rs29.39.0 325.4%  
Dividends per share (Unadj.) Rs2.002.25 88.9%  
Dividend yield (eoy) %0.42.0 18.3%  
Book value per share (Unadj.) Rs155.747.5 327.5%  
Shares outstanding (eoy) m804.51177.83 452.4%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x3.02.3 127.0%   
Avg P/E ratio x42.014.6 287.0%  
P/CF ratio (eoy) x18.412.3 149.2%  
Price / Book Value ratio x3.52.3 148.2%  
Dividend payout %15.529.6 52.6%   
Avg Mkt Cap Rs m434,51619,784 2,196.3%   
No. of employees `00023.0NA-   
Total wages/salary Rs m26,3381,221 2,158.0%   
Avg. sales/employee Rs Th6,349.1NM-  
Avg. wages/employee Rs Th1,143.0NM-  
Avg. net profit/employee Rs Th449.3NM-  
INCOME DATA
Net Sales Rs m146,3028,459 1,729.6%  
Other income Rs m2,287394 581.1%   
Total revenues Rs m148,5898,852 1,678.6%   
Gross profit Rs m24,7582,070 1,195.9%  
Depreciation Rs m13,229249 5,310.8%   
Interest Rs m1,59431 5,139.6%   
Profit before tax Rs m12,2222,184 559.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-70-225 31.1%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,798606 296.9%   
Profit after tax Rs m10,3541,353 765.2%  
Gross profit margin %16.924.5 69.1%  
Effective tax rate %14.727.7 53.0%   
Net profit margin %7.116.0 44.2%  
BALANCE SHEET DATA
Current assets Rs m87,3704,355 2,006.1%   
Current liabilities Rs m33,0811,792 1,846.1%   
Net working cap to sales %37.130.3 122.4%  
Current ratio x2.62.4 108.7%  
Inventory Days Days8744 195.6%  
Debtors Days Days6225 252.6%  
Net fixed assets Rs m111,5673,025 3,688.2%   
Share capital Rs m1,609179 900.9%   
"Free" reserves Rs m123,6458,243 1,500.1%   
Net worth Rs m125,2548,453 1,481.8%   
Long term debt Rs m36,45411 340,687.9%   
Total assets Rs m209,53210,557 1,984.8%  
Interest coverage x8.771.4 12.1%   
Debt to equity ratio x0.30 22,991.9%  
Sales to assets ratio x0.70.8 87.1%   
Return on assets %5.713.1 43.5%  
Return on equity %8.316.0 51.6%  
Return on capital %8.523.5 36.2%  
Exports to sales %34.213.3 257.1%   
Imports to sales %8.33.3 249.5%   
Exports (fob) Rs m50,0501,126 4,446.1%   
Imports (cif) Rs m12,203283 4,315.0%   
Fx inflow Rs m51,0661,146 4,455.7%   
Fx outflow Rs m17,678355 4,975.5%   
Net fx Rs m33,388791 4,222.1%   
CASH FLOW
From Operations Rs m23,8241,485 1,604.4%  
From Investments Rs m-13,127-620 2,118.9%  
From Financial Activity Rs m-13,239-753 1,759.3%  
Net Cashflow Rs m-2,478113 -2,196.8%  

Share Holding

Indian Promoters % 16.0 68.9 23.2%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 4.7 259.6%  
FIIs % 23.7 7.5 316.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 19.0 137.9%  
Shareholders   161,166 23,730 679.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   ELDER PHARMA  TTK HEALTHCARE  SHASUN PHARMA  STRIDES SHASUN LTD  J.B.CHEMICALS  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 22, 2017 (Close)

TRACK CIPLA

CIPLA - SHASUN PHARMA COMPARISON

COMPARE CIPLA WITH

MARKET STATS